國家衛生研究院 NHRI:Item 3990099045/10885
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 861809      線上人數 : 792
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10885


    題名: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    作者: Yoshino, T;Arnold, D;Taniguchi, H;Pentheroudakis, G;Yamazaki, K;Xu, RH;Kim, TW;Ismail, F;Tan, IB;Yeh, KH;Grothey, A;Zhang, S;Ahn, JB;Chong, D;Chen, LT;Kopetz, S;Eguchi-Nakajima, T;Ebi, H;Ohtsu, A;Cervantes, A;Muro, K;Tabernero, J;Minami, H;Ciardiello, F;Douillard, JY
    貢獻者: National Institute of Cancer Research
    摘要: The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (CSCO), Korea (KACO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
    日期: 2018-01
    關聯: Annals of Oncology. 2018 Jan;29(1):44-70.
    Link to: http://dx.doi.org/10.1093/annonc/mdx738
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000423741500013
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85041205697
    顯示於類別:[陳立宗] 期刊論文

    文件中的檔案:

    檔案 大小格式瀏覽次數
    PUB29155929.pdf1375KbAdobe PDF241檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋